4 terminated. 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 4 |
| Phase 3 | 1 | Terminated 1 |
Follow lanreotide: new trials by email Literature Review of lanreotide trials Research Report on lanreotide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres Lanreotide, Y-90 microspheres - Neuroendocrine Tumors, Gastrointestinal Neoplasms | Phase 2 | Terminated | SCRI Development Innovations, LLC | 6 | 2017-07-28 | 2023-12-05 |
| A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) lanreotide, Placebo - Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours | Phase 2 / Phase 3 | Terminated | Federation Francophone de Cancerologie Digestive | 53 | 2015-01-01 | 2023-01-18 |
| Quality of Life in Patients With Inoperable Malignant Bowel Obstruction lanreotide (Autogel formulation) - Intestinal Obstruction | Phase 2 | Terminated | Ipsen | 43 | 2015-01-01 | 2019-11-22 |
| Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days - Thyroid-Associated Ophthalmopathy | Phase 2 | Terminated | Ipsen | 5 | 2006-01-01 | 2020-06-02 |
Carcinoid Tumor (1) · Gastrointestinal Neoplasms (1) · Graves Ophthalmopathy (1) · Intestinal Obstruction (1) · Neoplasm Metastasis (1) · Neuroendocrine Tumors (1)
Ipsen (2) · Federation Francophone de Cancerologie Digestive (1) · SCRI Development Innovations, LLC (1)
Belgium (1) · France (1) · Germany (1) · Italy (1) · Spain (1) · United Kingdom (1) · United States (1)
Come Lepage, Pr (1) · David Spigel, M.D. (1)
2004 (1)